Previsión
El precio objetivo medio de los analistas es de 121,03 € (+108,64 %). La mediana es de 136,70 € (+135,65 %).
| Comprar |
14 |
| Mantener |
9 |
| Vender |
3 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Corcept Therapeutics raises guidance after strong quarter and record volume
Corcept reports a massive jump in profit and an increase in revenue on record trading volume, prompting management to sharply raise its full-year forecast. The new oncology drug Lifyorli is expected to deliver further growth in the medium term. Management is targeting annual sales of up to $5 billion by 2030. » Más en finanzen.net
Corcept Therapeutics reaches new all-time high after strong quarterly results
The stock of Corcept Therapeutics rose to an all-time high of $122.50 and is currently trading at $121.31, corresponding to a market capitalization of $13.13 billion. In the second quarter of 2026 the company reported revenue of $256.1 million (+32% year-on-year) and raised its full-year guidance to $1.1–1.2 billion. Analysts responded with price-target increases and positive assessments, while InvestingPro currently rates the stock as overvalued relative to its fair value. » Más en de.investing.com
Corcept Therapeutics reaches 52-week high at $95.18
Shares of Corcept Therapeutics rose to a 52-week high of $95.18, gaining 152% over the past six months and 163% year-to-date. The company has resubmitted the New-Drug-Application for Relacorilant to the FDA for the treatment of Cushing’s syndrome; the review is expected to take six months. At ASCO, Corcept presented data from the phase‑3 ROSELLA study showing a 35% reduction in risk of death with Lifyorli (Relacorilant) plus nab‑paclitaxel. First-quarter 2026 revenues of about $165 million were below consensus, but analysts still raised price targets and reiterated buy ratings. » Más en de.investing.com
Corcept resubmits approval application for relacorilant to treat Cushing's syndrome to FDA
Corcept resubmitted the New Drug Application for relacorilant to the FDA and included additional analyses of the originally requested data. The company expects a six-month review period; the submission is based on data from the GRACE study, the phase III GRADIENT study, a long-term extension and earlier development phases. According to Corcept, relacorilant improves symptoms of Cushing's syndrome without certain side effects, received orphan-drug status and is also already FDA-approved as Lifyorli for platinum-resistant ovarian cancer. Investors reacted positively; the stock is up about 141% year-to-date and the company has a market capitalization of $8.79 billion. » Más en de.investing.com
Corcept shows phase‑3 data: relacorilant plus nab‑paclitaxel extends survival in ovarian cancer
In the ROSELLA trial, relacorilant (Lifyorli) in combination with nab‑paclitaxel reduced the risk of death by 35% versus nab‑paclitaxel alone (hazard ratio 0.65; p=0.0004) and increased median overall survival to 16.0 versus 11.9 months. A biomarker test was not required; subgroups with a short taxane‑free interval showed similar effects. Lifyorli was approved by the FDA in March 2026 for the combination therapy in platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The stock is up 96% so far in 2026 (week +13.6%); frequent adverse events and 35% serious adverse events in the combination group were reported. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2022, Corcept Therapeutics ya ha pagado 0,26 € en dividendos. El último pago fue en marzo de 2022.
Datos financieros
En el último trimestre, Corcept Therapeutics tuvo unos ingresos de 300,59 M € y un beneficio neto de 111,93 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 300,59 M | 69,89 % |
| Beneficio bruto | 296,52 M | 71,38 % |
| Beneficio neto | 111,93 M | 567,83 % |
| EBITDA | 107,12 M | 699,66 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 6761,44 M € |
Número de acciones | 109,44 M |
Máximo/mínimo de 52 semanas | 115,18 € - 26,12 € |
| Dividendos | No |
Beta | 0,45 |
Ratio P/E | 45,19 |
Ratio PEG | 0,90 |
Ratio P/B | 8,67 |
Ratio P/S | 7,70 |
Perfil de la empresa
Corcept Therapeutics Incorporated descubre, desarrolla y comercializa fármacos para el tratamiento de trastornos metabólicos, oncológicos y neuropsiquiátricos graves en Estados Unidos. La compañía ofrece los comprimidos de Korlym (mifepristona) como medicamento oral de administración diaria para el tratamiento de la hiperglucemia secundaria a hipercortisolismo en pacientes adultos con síndrome de Cushing endógeno, que padecen diabetes mellitus tipo 2 o intolerancia a la glucosa, y que han fracasado en la cirugía o no son candidatos a someterse a ella. Está desarrollando relacorilant para tratar a pacientes con síndrome de Cushing; y nab-paclitaxel en combinación con relacorilant, que ha completado un ensayo clínico de fase II para tratar a pacientes con tumores ováricos avanzados, así como para el tratamiento del exceso de cortisol. La compañía también está desarrollando un modulador selectivo del cortisol para tratar a pacientes con cáncer de próstata metastásico resistente a la castración; un modulador selectivo del cortisol para el tratamiento del aumento de peso inducido por antipsicóticos y otros trastornos; y ensayos de expresión del gen FKBP5. Corcept Therapeutics Incorporated se fundó en 1998 y tiene su sede en Menlo Park, California.
| Nombre | Corcept Therapeutics |
| CEO | Joseph K. Belanoff |
| Sede | Redwood City,
ca Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Productos farmacéuticos |
| Salida a bolsa | 14/04/2004 |
| Empleados | 730 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | CORT |
London Stock Exchange | 0I3Q.L |
Frankfurt | HTD.F |
Düsseldorf | HTD.DU |
London | 0I3Q.L |
SIX | HTD.SW |
München | HTD.MU |
Milan | 1CORT.MI |